LB Pharmaceuticals received a buy rating with a base valuation of $85 per share and potential upside to $150 if its Phase 3 clinical trials and drug differentiation succeed. The key drug, LB-102, shows promise due to its effective brain receptor targeting at lower doses, potentially reducing side effects and allowing once-daily dosing. The main uncertainty is whether the drug's unique 5-HT7 receptor activity offers clinical benefits beyond existing treatments. The critical catalyst will be the Phase 3 NOVA-2 trial results expected in the first half of 2027. LB Pharmaceuticals is considered a high-risk, high-reward investment with sufficient cash to operate beyond mid-2029.
LB Pharmaceuticals is the subject of this update, with Pluang providing health-sector market data as context. As of Sep 18, 2026 15:41 WIB, among 91 priced health-sector US stocks on Pluang, 40 rose and 41 fell. Notable movers include ASND at USD 253.09 with a 1-day change of +5.88% and Pluang order activity showing 71% Buy, and ABEO at USD 5.79 with a 1-day change of +3.58% and 100% Buy order activity.
Gulfport Energy's Vice President, Willrath, sold 325 shares of the company's stock, generating $59,400 from the transaction. This insider sale may indicate personal financial decisions or portfolio adjustments but does not necessarily reflect the com...
Ethereum plans to activate its major Glamsterdam upgrade on the Sepolia testnet on October 6, 2026, introducing Enshrined Proposer-Builder Separation (ePBS) to increase block capacity and transaction processing time. However, developers have raised s...
NEAR Protocol's token surged 45% from $2.34 to $3.45 within three days, driven by the launch of confidential perpetual trading via Hyperliquid and a new rewards initiative called Push to $3.33. The platform now supports private leveraged trading acro...
TransMedics is experiencing a slowdown in liver transplant growth, increasing its reliance on international markets and other organ transplants like heart, lung, and kidney to drive future growth. Delays in heart and lung clinical trials have created...
SK hynix is rated a strong buy as it transitions from cyclical commodity memory to a high-margin AI infrastructure business. Strategic moves like a KRW 40 trillion share cancellation, new product launches (HBF and SALT-KV), and long-term agreements o...
